BIOSTAR PHARM-B (02563) announced its mid-term performance, reporting a net loss of 26.596 million yuan, a year-on-year reduction of 50.8%.

BIOSTAR PHARM-B (02563) announced its mid-year results for 2026, reporting revenue of 36.635 million yuan, an increase of 147.8% year-on-year; gross profit of 34.08 million yuan, up 147.9% year-on-year; and a net loss of 26.596 million yuan, narrowed by 50.8% year-on-year; with a loss per share of 0.07 yuan. The announcement stated that the revenue growth was primarily due to the continuous expansion of market coverage for the product Youtaidelong Injection, which drove an increase in product sales.